DSY DASSAULT SYSTEMES SA

Medidata Sees Strong Momentum with Key Customer Wins, Advances in CNS and Digital Therapeutics, and Expanded Market Leadership

Medidata Sees Strong Momentum with Key Customer Wins, Advances in CNS and Digital Therapeutics, and Expanded Market Leadership

Continued focus on patients, customers, and innovation helping to drive new advances in clinical research for life science companies

NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- , a Dassault Systèmes brand, has seen significant momentum and reaffirmed its vision to progress the life sciences industry forward, securing new enterprise agreements with several large customers, a strengthened industry partnership in central nervous system (CNS), a strengthened presence in digital therapeutics, and expanded leadership. Medidata further solidified its market leadership to transform life sciences through its focus on innovative, AI-powered solutions and strengthened approach on , extending the brand’s impact beyond clinical trials through commercialization and the delivery of more accessible, effective therapies to patients.

“Medidata continues to drive innovation across the life sciences ecosystem,” said Anthony Costello, CEO, Medidata. “We’ve received significant industry recognition for Medidata Clinical Data Studio, an integral offering within our Data Experience, as well as our partnerships with Click Therapeutics and Cogstate, which are generating strong interest with customers. These bold moves will deliver new solutions for patients, sites, and sponsors and represent concrete steps towards improving outcomes and advancing healthcare.”

Driving Industry-Wide Transformation

Expanding on its , Medidata launched the to elevate the site voice, boost study engagement, and improve technology compliance in research. It also became the first life sciences brand to integrate data from the , hosted by the (NIHR), into , streamlining the study start up process and improving budget precision by up to 80%.

Advancing CNS and Digital Therapeutics

To deliver a comprehensive CNS trial experience for patients and researchers, Medidata, in partnership with , has developed a unified, deeply integrated solution to optimize endpoint data quality and reduce operational complexity. Additionally, Medidata partnered with , reinforcing its commitment to supporting patients beyond clinical trials and along their healthcare journey through innovations such as software-enhanced drugs. Together, the partnerships with Cogstate and Click Therapeutics will improve the patient and study experience and deliver new, innovative solutions for sites, sponsors and life sciences companies.

Expanding Market Leadership

Medidata continued to set the industry standard in clinical trial innovation, securing new agreements with a large enterprise pharmaceutical company, two of the top 10 biopharma manufacturers, and a leading clinical research organization, . These collaborations further reinforce Medidata’s position as the industry preferred trusted partner for clinical trials, providing cutting-edge AI and machine learning capabilities to accelerate drug development and enhance patient outcomes.

Award-Winning Technology and Innovation

Medidata AI-powered solutions continue to earn industry accolades. In the first quarter, , was recognized as a top technology for improving data quality and accelerating study timelines by the (SCOPE) and . Medidata was also inducted into the , validating its relentless commitment to innovation and leadership in shaping the future of clinical trials. Additionally, as a result of the Cogstate collaboration, Medidata was recognized with the for Best Clinical Trial Technology Solution Provider, recognizing the impact and innovation behind this joint effort.

Strengthened Leadership

In January, Medidata bolstered its to further deliver patient-centered, customer-focused innovation with appointments of new executives and , along with the promotion of to chief patient officer.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: .

Contact:

Medidata PR



Analyst Relations



EN
03/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DASSAULT SYSTEMES SA

 PRESS RELEASE

NOTICE TO DISREGARD -- Medidata Solutions, Inc.

NOTICE TO DISREGARD -- Medidata Solutions, Inc. NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- We are advised by Medidata Solutions, Inc. that journalists and other readers should disregard the news release, "Medidata Sees Strong Momentum with Key Customer Wins, Advances in CNS and Digital Therapeutics, and Expanded Market Leadership" issued June 3, 2025 at 8:00am ET, over GlobeNewswire.

 PRESS RELEASE

Medidata Sees Strong Momentum with Key Customer Wins, Advances in CNS ...

Medidata Sees Strong Momentum with Key Customer Wins, Advances in CNS and Digital Therapeutics, and Expanded Market Leadership Continued focus on patients, customers, and innovation helping to drive new advances in clinical research for life science companies NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- , a Dassault Systèmes brand, has seen significant momentum and reaffirmed its vision to progress the life sciences industry forward, securing new enterprise agreements with several large customers, a strengthened industry partnership in central nervous system (CNS), a strengthened presenc...

Ahmed Ben Salem ... (+3)
  • Ahmed Ben Salem
  • Bruno Cavalier
  • Steven Boumans
FP TOTAL SE
TKA THYSSENKRUPP AG
EQNR EQUINOR ASA
MT ARCELORMITTAL SA
GALP GALP ENERGIA SGPS SA CLASS B
APAML APERAM SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
LI KLEPIERRE SA
COV COVIVIO SA
ROG ROCHE HOLDING LTD
OUT1V OUTOKUMPU OYJ
GFC GECINA SA
SSAB A SSAB AB CLASS A
NXI NEXITY SA CLASS A
NOVN NOVARTIS AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
FLY SOCIETE FONCIERE LYONNAISE SA
GYC GRAND CITY PROPERTIES SA
MERY MERCIALYS SA
SZG SALZGITTER AG
EL ESSILORLUXOTTICA SA
WHA WERELDHAVE N.V.
KCO KLOECKNER & CO SE
BLND BRITISH LAND COMPANY PLC
BRBY BURBERRY GROUP PLC
KOF KAUFMAN & BROAD SA
JCQ JACQUET METALS SA
KER KERING SA
ALTA ALTAREA SCA
VNA VONOVIA SE
VOE VOESTALPINE AG
ACX ACERINOX SA
ENI ENI S.P.A.
XIOR XIOR STUDENT HOUSING N.V.
BAS BASF SE
SAN SANOFI
ICAD ICADE SA
01913 PRADA S.P.A.
REP REPSOL SA
BYG BIG YELLOW GROUP PLC
COFB COFINIMMO SA
CAI CA IMMOBILIEN ANLAGEN AG
TEG TAG IMMOBILIEN AG
VASTB VASTNED RETAIL BELGIUM NV
PSPN PSP SWISS PROPERTY AG
UBS UBM DEVELOPMENT AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
CARM CARMILA SAS
LEG LEG IMMOBILIEN AG
MONC MONCLER SPA
CPINV CARE PROPERTY INVEST SA
SAFE SAFESTORE HOLDINGS PLC
ARG ARGAN SA
VGP VGP NV
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
NN NN GROUP N.V.
MERLIN MERLIN PROPERTIES SOCIMI S.A.
DKG DEUTSCHE KONSUM REIT-AG
AZN ASTRAZENECA PLC
BP. BP P.L.C.
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
NSI NSI N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
AEDAS AEDAS HOMES SA
WDP WAREHOUSES DE PAUW SCA
DSY DASSAULT SYSTEMES SA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
SHEL SHELL PLC
ONE ONE UNITED PROPERTIES SA
GSK GSK PLC
SHUR SHURGARD SELF STORAGE LIMITED
H2O HIDROELECTRICA S.A.
NOVO B NOVO NORDISK A/S

ResearchPool Subscriptions

Get the most out of your insights

Get in touch